News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioSpace (DHX) Temperature Poll: After Bristol-Myers Squibb (BMY) Wonder Drug Meets Endpoints, Will FDA Process Be Up to Snuff?



6/29/2015 12:13:53 PM

Our most popular story last week was about a new wonder drug that wowed the FDA. An experimental anticoagulant drug under joint development between Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) met all primary and secondary endpoints in a Phase III study determining safety and efficacy—and our readers responded. The hope now is it will be sped to patients as fast as possible.

That’s lead BioSpace to ask, what do you think about the drug approval process in this country? Let us know your ideas.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES